SMTL ID : 7pbc.1

Crystal structure of engineered TCR (796) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.04 Å

Oligo State

hetero-1-1-1-1-mer

Ligands

1 x GLY- LEU- TYR- ASP- GLY- MET- GLU- HIS- LEU: Melanoma-associated antigen 10(Non-covalent)

GLY-LEU-TYR-ASP-GLY-MET-GLU-HIS-LEU.1: 47 residues within 4Å: Chain A: M.6, Y.8, F.10, F.34, M.46, Y.60, E.64, K.67, V.68, H.71, T.74, V.77, D.78, T.81, L.82, Y.85, V.96, R.98, Y.100, H.115, Y.117, Y.124, I.125, T.144, K.147, W.148, V.153, Q.156, L.157, Y.160, W.168, Y.172 Chain C: Q.32, R.93, G.94, T.95, G.96, R.97, R.98 Chain D: D.31, Y.32, Y.34, V.51, S.95, F.96, T.97, D.98 44 PLIP interactions: 28 interactions with chain A, 10 interactions with chain C, 6 interactions with chain D Hydrophobic interactions: A:Y.8, A:F.10, A:V.68, A:D.78, A:L.82, A:Y.100, A:Y.117, A:Y.124, A:V.153, A:V.153, A:L.157, A:Y.160, A:Y.160, D:Y.32, D:T.97 Hydrogen bonds: A:Y.8, A:E.64, A:K.67, A:H.71, A:D.78, A:Y.100, A:Y.100, A:T.144, A:W.148, A:Y.160, C:R.93, C:R.93, C:G.96, C:R.98, C:R.98, D:D.31, D:V.51 Water bridges: A:T.81, A:T.81, A:R.98, A:H.115, C:G.94, C:T.95, C:R.98, D:D.31, D:Y.32 Salt bridges: A:K.147, C:R.93, C:R.98

3 x GOL: GLYCEROL(Non-functional Binders)

GOL.2: 7 residues within 4Å: Chain A: S.5, R.7, F.9, Y.28, D.30, D.31 Chain B: Y.64 2 PLIP interactions: 2 interactions with chain A Water bridges: A:S.5, A:D.30 GOL.3: 6 residues within 4Å: Chain A: Y.86, Q.88, H.94, Y.119, D.120, K.122 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:Q.88, A:D.120, A:K.122 GOL.4: 6 residues within 4Å: Chain A: F.110, E.162, G.163, V.166, E.167, R.170 5 PLIP interactions: 5 interactions with chain A Hydrogen bonds: A:E.162, A:E.167, A:R.170 Water bridges: A:R.170, A:R.170

1 x CL: CHLORIDE ION(Non-functional Binders)

CL.5: 5 residues within 4Å: Chain D: G.54, T.56, S.68, R.69, L.70 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Simister, P.C. et al., Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy. J Immunother Cancer (2022)

Release Date

2022-08-03

Peptides

MHC class I antigen: A
Beta-2-microglobulin: B
T-cell receptor (TRAV/TRAC): C
T-cell receptor (TRBV/TRBC): D

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
CCC

B
DDD

C
AAA

D
BBB

MHC class I antigen

Beta-2-microglobulin

T-cell receptor (TRAV/TRAC)

T-cell receptor (TRBV/TRBC)

Related Entries With Identical Sequence